Response to “Perspectives from the field in response to ‘It is time to revise our approach to registering antimicrobial agents [by the Environmental Protection Agency] for health care settings’”

详细信息    查看全文

• 作者：Evelyn Alvarez ; MPH
• 刊名：American Journal of Infection Control
• 出版年：2017
• 出版时间：1 January 2017
• 年：2017
• 卷：45
• 期：1
• 页码：100-102
• 全文大小：289 K
• 卷排序：45

文摘

We express our satisfaction with the responding author's agreement with our call to action to require clinical studies in the U.S. Environmental Protection Agency registration of antimicrobial surfaces. We reaffirm our stance on requiring clinical evidence before registration, and we present salient counterarguments as to why this should be of crucial importance to the scientific process. We address a discrepancy made in the response where the authors mistakenly ascribe clinical relevance to an in vitro study. We include a literature time line to visually juxtapose the robust body of in vitro studies to the paucity of clinical studies of antimicrobial copper alloy surfaces. We highlight an ongoing University of California, Los Angeles study representative of the level of rigor we hope to see in clinical studies of antimicrobial surfaces.